List of Rinvoq drug patents

Rinvoq is owned by Abbvie Inc.

Rinvoq contains Upadacitinib.

Rinvoq has a total of 17 drug patents out of which 0 drug patents have expired.

Rinvoq was authorised for market use on 16 August, 2019.

Rinvoq is available in tablet, extended release;oral dosage forms.

Rinvoq can be used as treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tnf blockers, treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tnf blockers; treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers, treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, or when use of those therapies are inadvisable, treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tnf blockers; treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to one or more tnf blockers; treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blockers, treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers.

Drug patent challenges can be filed against Rinvoq from 2023-08-17.

The generics of Rinvoq are possible to be released after 17 October, 2036.

RINVOQ's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47221 ABBVIE INC Tricyclic compounds
Dec, 2030

(7 years from now)

US8962629 ABBVIE INC Tricyclic compounds
Jan, 2031

(7 years from now)

US11186584 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10981923 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US9951080 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9963459 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof
Oct, 2036

(13 years from now)

US10550126 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10995095 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10597400 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10519164 ABBVIE INC Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11198697 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10730883 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10344036 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11365198 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10202393 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11512092 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10981924 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

Do you want to check out RINVOQ patents from before 2022?
Exclusivity Exclusivity Expiration
New Indication (I) Dec 14, 2024
New Chemical Entity Exclusivity (NCE) Aug 16, 2024

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: 2023-08-17

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products,...

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

RINVOQ family patents

60

United States

10

Singapore

9

Japan

8

Australia

8

China

7

Canada

7

European Union

6

Israel

6

Korea, Republic of

6

Taiwan

5

Russia

4

Dominican Republic

4

Brazil

3

New Zealand

3

Peru

3

Costa Rica

3

Ukraine

3

Hong Kong

3

Mexico

3

Argentina

3

Hungary

2

Colombia

2

Ecuador

2

Croatia

2

Denmark

2

Spain

2

Uruguay

2

Malaysia

2

Chile

2

ME

2

Cyprus

2

Portugal

2

Poland

2

Norway

2

Slovenia

2

RS

2

South Africa

2

Lithuania

1

Luxembourg

1

Netherlands

1

Philippines

Rinvoq is owned by Abbvie.

Rinvoq contains Upadacitinib.

Rinvoq has a total of 5 drug patents out of which 0 drug patents have expired.

Rinvoq was authorised for market use on 16 August, 2019.

Rinvoq is available in tablet, extended release;oral dosage forms.

Rinvoq can be used as treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers, treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blockers, treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, or when use of those therapies are inadvisable, treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more tnf blockers.

Drug patent challenges can be filed against Rinvoq from 2023-08-17.

The generics of Rinvoq are possible to be released after 09 March, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11524964 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11535624 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11535625 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11535626 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11607411 ABBVIE Methods of treating Crohn's disease and ulcerative colitis
Mar, 2038

(14 years from now)

Do you want to check out RINVOQ patents from before 2022?
Exclusivity Exclusivity Expiration
New Indication (I) Dec 14, 2024
New Chemical Entity Exclusivity (NCE) Aug 16, 2024

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: 2023-08-17

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with moderately to severely active rheumatoid...

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic